Literature DB >> 29080451

Curcumin sensitizes lymphoma cells to DNA damage agents through regulating Rad51-dependent homologous recombination.

Qian Zhao1, Jiawei Guan1, Yuanhua Qin2, Peng Ren3, Zhiwei Zhang1, Jian Lv1, Shijie Sun4, Cuili Zhang1, Weifeng Mao5.   

Abstract

Curcumin is a natural compound isolated from the rhizome of Curcuma longa. It possesses anti-tumor activity through arresting cell cycles and promoting cell apoptosis. However, the effect of curcumin on DNA damage is not well defined. In this study, we investigated the effect of curcumin on inducing DNA damage and on sensitizing lymphoma cells to anti-tumoral DNA damage drugs. Western blot showed curcumin induced γ-H2AX foci in CH12F3 lymphoma cells, which suggests curcumin induces DNA breaks. In addition, curcumin decreased the expression of Rad51, which suggests curcumin induces DNA damage through regulating Rad51-dependant homologous recombination. Rad51-dependant homologous recombination is a vital DNA repair pathway for cancer cells to resist anti-tumoral DNA damage drugs, therefore, we studied the effect of curcumin on the sensitizing lymphoma cells to various chemotherapeutic drugs. We found low level of curcumin (5μM) sensitized lymphoma cells to anti-tumoral DNA damage agents including cisplatin, methyl methanesulfonate, hydroxyurea and camptothecin. We also found curcumin sensitized CH12F3 lymphoma cells to DNA-PK and PARP inhibitors. Flow cytometry analysis showed curcumin promoted apoptosis and western blot analysis confirmed curcumin activated caspase3-dependent apoptosis. Taken together, these results demonstrate that curcumin induces DNA damage through regulating Rad51-dependant homologous recombination and triggers caspase3-dependent apoptosis, more importantly, curcumin sensitizes lymphoma cells to various DNA damage drugs. Consequently, curcumin would be a potent agent for sensitizing lymphoma cells to anti-tumoral chemotherapeutic agents.
Copyright © 2017. Published by Elsevier Masson SAS.

Entities:  

Keywords:  Apoptosis; Curcumin; DNA damage; Homologous recombination; Rad51

Mesh:

Substances:

Year:  2017        PMID: 29080451     DOI: 10.1016/j.biopha.2017.09.078

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  6 in total

1.  Qin Huang formula enhances the effect of Adriamycin in B-cell lymphoma via increasing tumor infiltrating lymphocytes by targeting toll-like receptor signaling pathway.

Authors:  Weili Li; Lingling Lv; Ming Ruan; Jiayue Xu; Wenhua Zhu; Qiong Li; Xufeng Jiang; Lan Zheng; Weirong Zhu
Journal:  BMC Complement Med Ther       Date:  2022-07-11

2.  Targeting HR Repair as a Synthetic Lethal Approach to Increase DNA Damage Sensitivity by a RAD52 Inhibitor in BRCA2-Deficient Cancer Cells.

Authors:  Wei-Che Tseng; Chi-Yuan Chen; Ching-Yuh Chern; Chu-An Wang; Wen-Chih Lee; Ying-Chih Chi; Shu-Fang Cheng; Yi-Tsen Kuo; Ya-Chen Chiu; Shih-Ting Tseng; Pei-Ya Lin; Shou-Jhen Liou; Yi-Chen Li; Chin-Chuan Chen
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

Review 3.  Natural Compounds That Target DNA Repair Pathways and Their Therapeutic Potential to Counteract Cancer Cells.

Authors:  Francisco Alejandro Lagunas-Rangel; Rosa María Bermúdez-Cruz
Journal:  Front Oncol       Date:  2020-11-19       Impact factor: 6.244

4.  [Bortezomib interferes with DNA repair and exerts synergistic anti-multiple myeloma activity with doxorubicin].

Authors:  H L Tang; L Xu; X Q Chen
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-05-14

5.  Curcumin Inhibits ERK/c-Jun Expressions and Phosphorylation against Endometrial Carcinoma.

Authors:  Zhenxue Zhang; Pengfei Yi; Changchun Tu; Jiejie Zhan; Liping Jiang; Fanglin Zhang
Journal:  Biomed Res Int       Date:  2019-10-31       Impact factor: 3.411

6.  Curcumin: From a controversial "panacea" to effective antineoplastic products.

Authors:  De-Biao Xiang; Kai-Qiang Zhang; Ya-Ling Zeng; Qing-Zi Yan; Zhe Shi; Qin-Hui Tuo; Li-Mei Lin; Bo-Hou Xia; Ping Wu; Duan-Fang Liao
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.